Q1 2023 Results slide image

Q1 2023 Results

Company overview Innovation: Pipeline overview Financial review Financial performance Cardiovascular Immunology Ophthalmology Biosimilars Conclusions Neuroscience Global Health Appendix References Innovation: Clinical trials Abbreviations Oncology Other Biosimilars 91 Investor Relations | Q1 2023 Results NOVARTIS | Reimagining Medicine
View entire presentation